Document is current

Article History

Received: 6 May 2024

Accepted: 31 May 2024

First Online: 10 June 2024

Declarations

:

: The PANLIPSY study will be based on the Biological and Clinical Database for Pancreatic Adenocarcinoma (BACAP 2) cohort and the PAncreatic Disease Cohort of TOuLouse (PACTOL) both coordinated by Pr Barbara Bournet. The PANLIPSY study is an ancillary study of the BACAP 2 clinical trial. BACAP 2 protocol was approved by the “CPP Sud-Est II” ethics committee on June 2023 and registered on clinicaltrials.gov (NCT06128343). BACAP 2 is a prospective multicentric clinical trial dedicated to PDAC with extensive clinical information and multiple biological samples. BACAP 2 is structured around a data management center (CTD of the Cancer Institute of Montpellier, ICM) certified by INCa and a biological resource center also certified by INCa and with quality control labels (ISO 9001 and NFS 96–900). Data collection is prospective, and the patient's treatments are recorded during the follow-up until death. All the patients were informed of the study and voluntarily agreed to participate. All the patients who agreed to participate provided written consent.The PACTOL cohort was approved by “CPP Sud-Est III” ethics committee in March 2023 and was registered on clinicaltrials.gov (NCT05824403). The transfer of biological samples between French and European partners have been authorized by the ethics committees.

: All participants will be given written information.

: Catherine Alix-Panabières received grant support for PANLIPSY from Menarini©